Immunosuppressants / Biologics / DMARDs
High-yield Verified · Jul 2026Prototype: methotrexate
Methotrexate, the calcineurin inhibitors, and the “-mab” biologics — how we deliberately weaken immunity, and the screening that makes it safe.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 When the immune system is the problem
Most anti-infectives in this system help immunity attack a germ. This class does the opposite — it turns immunity down. That is needed in two situations: autoimmune disease (rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus), where the immune system attacks the body’s own tissue, and organ transplantation, where it would otherwise reject the graft.
The umbrella terms are worth untangling. DMARDs (disease-modifying antirheumatic drugs) are drugs that slow autoimmune joint destruction — methotrexate is the anchor. Calcineurin inhibitors (tacrolimus, cyclosporine) are the backbone of transplant anti-rejection. Biologics are lab-engineered proteins (the “-mab” monoclonal antibodies and fusion proteins like etanercept) that block one precise immune signal — most famously TNF-α, a master inflammatory cytokine.
02 Three ways to brake immunity
Methotrexate is a folate antagonist: it inhibits dihydrofolate reductase, starving cells of the folate needed to make DNA. Rapidly dividing cells — including activated immune cells — are hit hardest. At high oncologic doses it kills cancer; at low weekly doses it calms autoimmune inflammation. The single most dangerous fact about it: low-dose methotrexate is taken WEEKLY, not daily — accidental daily dosing is a classic, sometimes fatal, error.
Calcineurin inhibitors block the enzyme calcineurin inside T-cells, preventing IL-2 production — the signal T-cells need to proliferate. No IL-2, no T-cell army to reject the organ. TNF inhibitors mop up or block TNF-α, switching off a central driver of inflammation in RA, psoriasis, and IBD.
03 The shared price — infection, malignancy, and the screening rule
A weakened immune system cannot fully distinguish "helpful" suppression from "dangerous" — so every drug here raises the risk of serious infection (including reactivation of dormant infections) and, over time, malignancy (especially lymphoma). This is the boxed-warning territory of the biologics.
The high-yield safety rule follows directly: before starting a TNF inhibitor, screen for latent tuberculosis (PPD/IGRA) and hepatitis B — because suppressing TNF-α can let a walled-off, silent TB or hepatitis roar back to life. During therapy, live vaccines are contraindicated (a weakened immune system can’t safely contain even an attenuated organism), any fever/infection is treated seriously, and methotrexate patients take folic acid to blunt toxicity — with leucovorin (folinic acid) as the rescue antidote for overdose.
Drug names
Indications
- Autoimmune disease: rheumatoid arthritis, psoriasis/psoriatic arthritis, inflammatory bowel disease (Crohn’s, ulcerative colitis), lupus
- Prevention and treatment of solid-organ transplant rejection (calcineurin inhibitors)
- Methotrexate also: certain cancers (high dose), ectopic pregnancy, severe psoriasis
Mechanism of action
Methotrexate inhibits dihydrofolate reductase, depleting reduced folate and blocking DNA/RNA synthesis in proliferating cells (anti-inflammatory at low dose, cytotoxic at high dose). Calcineurin inhibitors (tacrolimus, cyclosporine) block calcineurin-mediated T-cell activation, reducing IL-2 and T-cell proliferation. TNF inhibitors bind and neutralize tumor necrosis factor-α, a pivotal pro-inflammatory cytokine.
Therapeutic effects — what you'll see working
Success is disease control — fewer flares, preserved joints, an accepted transplant — at the lowest immunosuppression that keeps infection and malignancy risk acceptable. It is always a risk–benefit balance.
- Reduced autoimmune inflammation
- DMARDs and TNF inhibitors slow joint/tissue destruction, easing pain, swelling, and long-term disability.
- Graft survival
- Calcineurin inhibitors suppress the T-cell response that would otherwise reject a transplanted organ.
- Targeted cytokine blockade
- Biologics silence one precise signal (e.g., TNF-α), often controlling disease that failed conventional DMARDs.
Adverse effects
Beyond the universal infection/malignancy risk, each agent adds its own signature toxicity — methotrexate the marrow/liver/lung, calcineurin inhibitors the kidney.
Contraindications
Contraindications gather where added immunosuppression, or a specific organ toxicity, is unacceptable.
When to hold
Assess before giving — these findings mean hold the dose and act.
Labs & levels
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Sources
- Methotrexate — DHFR/folate mechanism, weekly dosing, hepatotoxicity/myelosuppression, leucovorin rescue — StatPearls (NCBI)
- Tumor Necrosis Factor Inhibitors — boxed warning (serious infection, malignancy), TB/HBV screening — StatPearls (NCBI)
- Tacrolimus — calcineurin/IL-2 mechanism, nephrotoxicity, CYP3A4 interactions, FDA boxed warnings — StatPearls (NCBI)
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.